Kuauhyama Luna-Ortiz1, Veronica Villavicencio-Valencia2, Alfredo Rodríguez-Falconi2, Nathalie Peteuil3, Adalberto Mosqueda-Taylor4. 1. Departament of Head and Neck Surgery, Instituto Nacional de Cancerología, México, USA ; Department of General Surgery, Hospital General Dr. Manuel Gea Gonzalez, México, USA. 2. Departament of Head and Neck Surgery, Instituto Nacional de Cancerología, México, USA. 3. Universidad Nacional Autonoma de Mexico, Facultad de Psicologia, México, USA. 4. Departamento de Atención a la Salud, Universidad Autónoma Metropolitana Xochimilco, México, USA.
Abstract
OBJECTIVE: To analyze the demographic data, clinical behavior, management (surgery/radiotherapy), disease-free survival (DFS) and overall survival (OS) in Mexican Mestizos with adenoid cystic carcinoma (ACC). MATERIAL AND METHODS: A retrospective study comprising all cases with histologic diagnosis of ACC of the head and neck treated from 1986 to 2012. RESULTS: There were 101 cases (69 women and 32 men), with a mean age of 50 years; mean evolution time before diagnosis was 25 months (range 1-180 months). Most tumors involved maxillary sinus (25.8 %), followed by hard palate (15.9 %) and parotid gland (10.9 %). Surgery was the treatment in 81 cases (80.2 %), radiotherapy alone in 3 cases (3 %), chemo-radiotherapy in 4 cases (4 %) and 13 cases (12.9 %) did not receive any treatment. Post-surgery adjuvant radiotherapy was used in 58 cases (57.4 %); 6 cases (5.9 %) had adjuvant chemo-radiotherapy after surgery and 37 (36.6 %) cases did not receive any adjuvant treatment. Mean follow-up time was 52 months (range 1-288 months). Histologic patterns were cribriform (50.5 %), solid (28.7 %), and tubular (11.9 %) types. OS was 57.6 % and 42.3 % at 5 and 10 years respectively. DFS was 57.8 % at 5 years and 49.7 % at 10 years. CONCLUSIONS: Initial management in most cases within this series was surgery followed by radiotherapy. There is more to learn about real benefits of molecular therapies. There were no significant differences in DFS and OS depending on site of involvement. OS did not show statistically significant differences amongst patients with positive and negative lymph nodes.
OBJECTIVE: To analyze the demographic data, clinical behavior, management (surgery/radiotherapy), disease-free survival (DFS) and overall survival (OS) in Mexican Mestizos with adenoid cystic carcinoma (ACC). MATERIAL AND METHODS: A retrospective study comprising all cases with histologic diagnosis of ACC of the head and neck treated from 1986 to 2012. RESULTS: There were 101 cases (69 women and 32 men), with a mean age of 50 years; mean evolution time before diagnosis was 25 months (range 1-180 months). Most tumors involved maxillary sinus (25.8 %), followed by hard palate (15.9 %) and parotid gland (10.9 %). Surgery was the treatment in 81 cases (80.2 %), radiotherapy alone in 3 cases (3 %), chemo-radiotherapy in 4 cases (4 %) and 13 cases (12.9 %) did not receive any treatment. Post-surgery adjuvant radiotherapy was used in 58 cases (57.4 %); 6 cases (5.9 %) had adjuvant chemo-radiotherapy after surgery and 37 (36.6 %) cases did not receive any adjuvant treatment. Mean follow-up time was 52 months (range 1-288 months). Histologic patterns were cribriform (50.5 %), solid (28.7 %), and tubular (11.9 %) types. OS was 57.6 % and 42.3 % at 5 and 10 years respectively. DFS was 57.8 % at 5 years and 49.7 % at 10 years. CONCLUSIONS: Initial management in most cases within this series was surgery followed by radiotherapy. There is more to learn about real benefits of molecular therapies. There were no significant differences in DFS and OS depending on site of involvement. OS did not show statistically significant differences amongst patients with positive and negative lymph nodes.
Entities:
Keywords:
Adenoid cystic carcinoma; Head and neck; Salivary glands; Surgery
Authors: Alexander D Rapidis; Nikolaos Givalos; Hariklia Gakiopoulou; Gregory Faratzis; Spyros D Stavrianos; George A Vilos; Emmanuel E Douzinas; Efstratios Patsouris Journal: Oral Oncol Date: 2005-03 Impact factor: 5.337
Authors: Stijn van Weert; Elisabeth Bloemena; Isaäc van der Waal; Remco de Bree; Derek H F Rietveld; Joop D Kuik; C René Leemans Journal: Oral Oncol Date: 2013-06-14 Impact factor: 5.337
Authors: Danyel Elias da Cruz Perez; Fábio de Abreu Alves; Inês Nobuko Nishimoto; Oslei Paes de Almeida; Luiz Paulo Kowalski Journal: Oral Oncol Date: 2005-10-24 Impact factor: 5.337
Authors: Damon A Silverman; Thomas P Carlson; Deepak Khuntia; Richard T Bergstrom; Jerrold Saxton; Ramon M Esclamado Journal: Laryngoscope Date: 2004-07 Impact factor: 3.325